Results 121 to 130 of about 29,210 (297)

Btk inhibitor ibrutinib reduces inflammatory myeloid cell responses in the lung during murine pneumococcal pneumonia

Molecular Medicine, 2019
Background Streptococcus pneumoniae is a major causative agent in community-acquired pneumonia and sepsis. Overwhelming lung inflammation during pneumococcal pneumonia may hamper lung function.
Alexander P. de Porto, Zhe Liu, Regina de Beer, Sandrine Florquin, Onno J. de Boer, Rudi W. Hendriks, Tom van der Poll, Alex F. de Vos   +7 more
doaj   +1 more source

CD86, the double agent: Significance of CD86 expression in B‐cell malignancies

International Journal of Cancer, Volume 157, Issue 9, Page 1772-1780, 1 November 2025.
Abstract Bypassing the anti‐tumor functions of the immune system is one of the keys to tumor survival. Tumors, especially hematological tumors, produce or express factors that retune T and B cells to inhibit the immune response. Coreceptors CD28 and CTLA‐4, and their ligands, CD80 and CD86, are involved in the immunological synapse and play an ...
Gábor Barna, Gábor Szalóki, Ágnes Márk, Anna Hunyadi, Csilla Kriston   +4 more
wiley   +1 more source

Mitigating Ibrutinib‐Induced Ventricular Arrhythmia and Cardiac Dysfunction With Metformin

Cancer Innovation
Background Ibrutinib is a first‐line drug that targets Bruton's tyrosine kinase for the treatment of B cell cancer. However, cardiotoxicity induced by ibrutinib is a major side effect that limits its clinical use.
Pengsha Li, Daiqi Liu, Pan Gao, Ming Yuan, Zhiqiang Zhao, Yue Zhang, Zandong Zhou, Qingling Zhang, Meng Yuan, Xing Liu, Gary Tse, Guangping Li, Qiankun Bao, Tong Liu   +13 more
doaj   +1 more source

Electrocardiographic Changes Associated With Ibrutinib Exposure

Cancer Control, 2020
Although ibrutinib-associated atrial and ventricular arrhythmias have been well described, there is little information about ibrutinib’s effects on other electrocardiographic parameters, particularly the QT interval.
Michael G. Fradley MD, Allan Welter-Frost MD, Matthew Gliksman BS, Josephine Emole MD, Federico Viganego MD, Dae Hyun Lee MD, Bijal Shah MD, Julio C. Chavez MD, Javier Pinilla-Ibarz MD, PhD, Matthew B. Schabath PhD   +9 more
doaj   +1 more source

Ibrutinib and fungus: an invasive concern [PDF]

Blood, 2018
In this issue of Blood, Ghez et al report on 33 patients who developed invasive fungal infections during ibrutinib treatment, the majority of which were invasive aspergillosis, which supports the observation that fungal infections are a potential risk with ibrutinib ...
openaire   +3 more sources

Gender Disparities in Health‐Related Quality of Life in Patients With Chronic Lymphocytic Leukemia: Impact of Treatment Modality

European Journal of Haematology, Volume 115, Issue 5, Page 465-473, November 2025.
ABSTRACT In chronic lymphocytic leukemia (CLL), treatment initiation is deferred until clinical symptoms emerge, aiming to minimize treatment‐related burden and maintain health‐related quality‐of‐life (QoL). We examined gender differences in QoL among patients undergoing active surveillance versus targeted therapies.
Bushra Mahameed, Giora Sharf, Tamar Tadmor, Geffen Kleinstern   +3 more
wiley   +1 more source

Tandem combination of ASCT and CAR T‐cell therapy in highly refractory CNS lymphomas

British Journal of Haematology, EarlyView.
Lydia Montes, Sylvain Choquet, Madalina Uzunov, Véronique Morel, Marine Baron, Damien Roos‐Weil, Magalie Joris, Caroline Delette, Delphine Lebon, Nabih Azar, Carole Metz, Lucia Nichelli, Magali Le Garff‐Tavernier, Clémentine Boccon‐Gibod, Claire Lacan, Laetitia Souchet, Khê Hoang‐Xuan, Carole Soussain, Inès Boussen, Caroline Houillier   +19 more
wiley   +1 more source

Overall side‐effect bother consistently associated with early treatment discontinuation due to adverse events in four clinical trials with various cancer types and treatments

Cancer, Volume 131, Issue S2, 15 October 2025.
Abstract Background Overall side‐effect impact, the aggregated experience of multiple toxicities, can be captured with the single Functional Assessment of Cancer Therapy (FACT) item GP5 (“I am bothered by side effects of treatment”). The objective of this study was to evaluate the ability of item GP5 to indicate treatment tolerability by examining its ...
John Devin Peipert, Shaili Ganatra, Fengmin Zhao, Ju‐Whei Lee, Jessica Roydhouse, Edward H. Ip, Nathaniel O’Connell, Ruth C. Carlos, Noah Graham, Mary Lou Smith, Ilana F. Gareen, Ahmad A. Tarhini, Tait Shanafelt, Vered Stearns, Pamela J. Raper, David Cella, Robert Gray, Lynne I. Wagner   +17 more
wiley   +1 more source

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies [PDF]

, 2012
Ranjana H. Advani, Joseph J. Buggy, Jeff P. Sharman, Sonali M. Smith, Thomas E. Boyd, Barbara Grant, Kathryn S. Kolibaba, Richard R. Furman, Sara Rodríguez, Betty Chang, Juthamas Sukbuntherng, Raquel Izumi, Ahmed Hamdy, Eric Hedrick, Nathan Fowler   +14 more
openalex   +1 more source

Insights into PI3K/AKT signaling in B cell development and chronic lymphocytic leukemia

FEBS Letters, Volume 599, Issue 20, Page 2896-2910, October 2025.
This Review explores how the phosphoinositide 3‐kinase and protein kinase B pathway shapes B cell development and drives chronic lymphocytic leukemia, a common blood cancer. It examines how signaling levels affect disease progression, addresses treatment challenges, and introduces novel experimental strategies to improve therapies and patient outcomes.
Maike Buchner
wiley   +1 more source